Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accretion PharmaceuticalsNSE:ACCPL -0.40%23 Equity-to-Asset is 0.71 as of Mar. 2026, which is 255% above its 10-year median of 0.20. GuruFocus rates NSE:ACCPL with a GF Score™ of 23/100. The stock has 6 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Accretion Pharmaceuticals ranks better than 65.84% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Accretion Pharmaceuticals Equity-to-Asset Related Terms
Accretion Pharmaceuticals Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accretion Pharmaceuticals Equity-to-Asset Chart
Accretion Pharmaceuticals Annual Data
Trend
Mar22
Mar23
Mar24
Mar25
Mar26
Equity-to-Asset
0.17
0.19
0.20
0.38
0.71
Accretion Pharmaceuticals Semi-Annual Data
Sep25
Mar26
Equity-to-Asset
0.79
0.71
NSE:ACCPL vs LLY, JNJ, ABBV: Equity-to-Asset Comparison
For the Drug Manufacturers - General subindustry, Accretion Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accretion Pharmaceuticals Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Accretion Pharmaceuticals's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Accretion Pharmaceuticals's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Accretion Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accretion Pharmaceuticals (NSE:ACCPL) has a Equity-to-Asset of 0.71 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Accretion Pharmaceuticals and its competitors. This is 255% above median its historical median of 0.20. Over the past decade, Accretion Pharmaceuticals' Equity-to-Asset has ranged from 0.17 to 0.71. According to the industry distribution chart, Accretion Pharmaceuticals ranks #344 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 34.2%.
Is Accretion Pharmaceuticals' Equity-to-Asset too high?
Accretion Pharmaceuticals' current Equity-to-Asset of 0.71 is 255% above median its 10-year median of 0.20. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 0.71. The Drug Manufacturers industry median Equity-to-Asset is 0.60. Accretion Pharmaceuticals' value of 0.71 is 18.3% above this industry median. Based on the distribution chart, Accretion Pharmaceuticals ranks #344 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Accretion Pharmaceuticals has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Pharmaceuticals' Equity-to-Asset compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Accretion Pharmaceuticals ranks #344 out of 1007 companies for Equity-to-Asset. This puts Accretion Pharmaceuticals in the upper half of its industry. The industry median Equity-to-Asset is 0.60. Accretion Pharmaceuticals' value of 0.71 is 18.3% above this benchmark. Historically, Accretion Pharmaceuticals' own Equity-to-Asset has ranged from 0.17 to 0.71 over the past decade. While the company's 10-year median is 0.20 vs. the industry median of 0.60, Accretion Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accretion Pharmaceuticals's current Equity-to-Asset of 0.71 is 18.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Accretion Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accretion Pharmaceuticals's current Equity-to-Asset is 0.71, which is 255% above median its own 10-year median of 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Pharmaceuticals stock overvalued right now?
Accretion Pharmaceuticals (NSE:ACCPL) has a current Equity-to-Asset of 0.71. The current Equity-to-Asset is 0.71, which is 255% above median its 10-year median of 0.20 and 18.3% above the Drug Manufacturers industry median of 0.60. Accretion Pharmaceuticals' overall GF Score™ is 23/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Accretion Pharmaceuticals (NSE:ACCPL), the current Equity-to-Asset is 0.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accretion Pharmaceuticals Ltd is engaged in the manufacturing of Medicinal & Pharmaceutical Products. The company manufactures tablets, oral liquid, capsule, cream, ointment, mouthwash, dusting powder, gel, ear drops, lotion, shampoo, powder, syrup, among others.
23GF Score
Get the complete analysis for NSE:ACCPL
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ACCPL has been successfully added to your 
